Search | Clinical Trials Finder

Conditions: Anaemia
Interventions: Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas

Conditions: Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 30,486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease, Anemia
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 35
States / cities: Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more

Conditions: Nocturnal Enuresis, Anemia, Sickle Cell
Interventions: Desmopressin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 8 Years to 21 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Iron Deficiency Anemia
Interventions: Ferrous Sulfate Oral Product; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 29 Weeks to 33 Weeks
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Chronic Kidney Diseases, Chronic Heart Failure, Iron Deficiency Anemia
Interventions: Iron Sucrose; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Genetic Education and Counseling; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Dunwoody, Georgia • Chicago, Illinois • Portland, Maine + 9 more

Conditions: Anaemia
Interventions: GSK1278863, GSK1278863 matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more

Conditions: Anaemia
Interventions: Daprodustat (GSK1278863), Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 49
States / cities: Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more

Conditions: CKD Anemia in Stable Dialysis Patients
Interventions: Epoetin Alfa, Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 74
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more

Conditions: Doula Support, Postpartum, Postpartum Anaemia, Postpartum Depression (PPD)
Interventions: Doula-coordinated, Midwife-delivered postpartum care; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Iron Deficiency Anemia, Impaired Renal Function
Interventions: Ferric Carboxymaltose (FCM), Iron Sucrose (Venofer); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Crovalimab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 3
States / cities: Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey

Conditions: CKD, Chronic Kidney Diseases, Hepcidin, Ergocalciferol, Vitamin D, Iron-deficiency, Anemia
Interventions: Ergocalciferol 50000 UNT, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Anemia
Interventions: Inhaled Nitric Oxide, Placebo; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 2 Weeks and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Springfield, Massachusetts • Stony Brook, New York • Valhalla, New York + 1 more

Conditions: Anemia in Pregnancy
Interventions: Vitamin C; Dietary Supplement
Lead sponsor: Fetal Medicine Foundation; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more

Conditions: Anemia
Interventions: Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more

Conditions: Anemia in Pregnancy, Pre-eclampsia
Interventions: Neevo®, Prenatal vitamins; Other
Lead sponsor: Pamlab, L.L.C.; Industry
Eligibility: 21 Years to 39 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: Chickasha, Oklahoma • Norman, Oklahoma

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 11 more

Conditions: Chronic Kidney Disease, Anemia
Interventions: Epoetin, Peginesatide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Sacramento, California • San Diego, California • San Jose, California + 2 more

Conditions: Sickle Cell Disease Vaso-occlusive Crisis
Interventions: CSL889, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more

Conditions: Chronic Renal Failure Requiring Hemodialysis
Interventions: Epoetin Hospira; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 108
States / cities: Azusa, California • Bellflower, California • Commerce, California + 57 more

Search by objective public record fields.

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Risk Factors, Costs, and Impacts of ED Boarding

Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Donor Breast Milk 2

Iron Deficiency and FGF23 Regulation in CKD and HF

Methods in Education for Breast Cancer Genetics

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

The Goal is to Examine the Impact of Doula-coordinated, Midwife-delivered Postpartum Care Among Individuals With Preterm Births <34 Weeks' Gestation Requiring NICU Admission.

Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO

Effect of Ascorbic Acid Supplementation in Pregnancy on Anemia (AAA)

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin